Tom (Tomasz M.) Beer, M.D.
News
2021/2022
A commentary on: Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study. PracticeUpdate
Breast cancer early detection at HealthCentral.com. “For those cancers where we do have a proven technology, like mammography, the blood tests are being studied only in combination with standard screening,” says Tomasz Beer, M.D., a cancer researcher at Oregon Health & Science University in Portland, OR, who directed the GRAIL-sponsored study of the test. “They’re very unequivocally designed to complement the standard screening because the standard screening methods have been so well proven to save lives.”
Pathfinder study – The Associated Press interviews Tom Beer, M.D., and a Pathfinder study participant whose cancer was detected through a blood test that screens healthy people for many types of cancer by checking for DNA fragments shed by tumor cells. The story is picked up by The Washington Post, PBS News Hour, ABC News, Chicago Sun-Times and dozens of other media outlets nationwide.
Cancer test - The New York Times writes about the GRAIL cancer detection study that the Knight Cancer Institute is part of, saying the tests screen for cancers that often go undetected, but they are expensive and some experts worry they could lead to unnecessary treatments without saving patients' lives. Tomasz Beer, M.D., says, "We're at a point now where the blood tests are in their early days. Some people in an informed manner can choose to be early adapters": Yahoo News, Advisory Board.
Pathfinder study – KGW News, KOIN TV, and the Portland Business Journal report on the progress of the Pathfinder study, led by Tom Beer, M.D.
Early cancer detection –- In a The New York Times profile on gene sequencing producer Illumina's purchase of Grail, a startup that developed a blood test for the early detection of dozens of kinds of cancer, Tom Beer, M.D., discusses the OHSU Knight Cancer Institute's leadership in a clinical research study in collaboration with Grail: "Where this field is going to shake out is hard to know. But this approach has a lot of underlying scientific promise."
Cancer patients -- A The New York Times article includes recommendations for patients with cancer from experts around the country, including Tom Beer, M.D.
Prostate cancer – In a video interview with UroToday, Tom Beer, M.D., is one of several expert panelists discussing the topics of depression, bone health, and exercise in patients with prostate cancer.
Cancer early detection – A Men's Health article describes an OHSU patient's experience with the Pathfinder study, aimed to detect many forms of cancer with a blood draw. The patient was diagnosed with both early-stage leukemia and a slow-growing prostate cancer. Study leader Tom Beer, M.D., said: "Early detection is a major challenge in cancer today. Nearly seven out of ten cancer deaths are due to cancers for which there is no early detection recommended at all. We're flying blind."
Prostate cancer therapy – Tom Beer, M.D., discusses OHSU's role studying a new FDA-approved therapy for patients with a form of prostate cancer. He says: "This is a significant new treatment for patients with prostate cancer who previously had few options. FDA approval of this therapy could be a lifeline for many patients, and I am proud that OHSU helped bring this treatment to patients who desperately need it": OHSU News.
Cancer therapy -- Tomasz M. Beer, M.D., discusses the benefits and side effects of available treatments for advanced prostate cancer: Patient Power.
Prostate cancer -- In a Cancer Therapy Advisor story on outcomes for prostate cancer patients with persistent PSA levels after salvage radical prostatectomy, Tom Beer, M.D., says: "I think the study points to the importance of careful selection of patients most likely to benefit from salvage prostatectomy. The procedure is best offered to patients who have a high probability of success."
Prostate cancer – In a video interview with UroToday, Tom Beer, M.D., is one of several expert panelists discussing the topics of depression, bone health, and exercise in patients with prostate cancer.
Targeted Oncology: Future Directions for the Treatment of mCRPC, October 19, 2021
Uro Today Video Lecture from ASCO 2021: Updated Interim Efficacy and Safety Results from a Phase I/IIa Trial HPN424 in Metastatic Castration-Resistant Prostate Cancer (mCRPC), June 16, 2021
Video Commentary - Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Non-metastatic CRPC, Journal of Clinical Pathways, February 23, 2021
A commentary on: Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study. PracticeUpdate
Breast cancer early detection at HealthCentral.com. “For those cancers where we do have a proven technology, like mammography, the blood tests are being studied only in combination with standard screening,” says Tomasz Beer, M.D., a cancer researcher at Oregon Health & Science University in Portland, OR, who directed the GRAIL-sponsored study of the test. “They’re very unequivocally designed to complement the standard screening because the standard screening methods have been so well proven to save lives.”
Pathfinder study – The Associated Press interviews Tom Beer, M.D., and a Pathfinder study participant whose cancer was detected through a blood test that screens healthy people for many types of cancer by checking for DNA fragments shed by tumor cells. The story is picked up by The Washington Post, PBS News Hour, ABC News, Chicago Sun-Times and dozens of other media outlets nationwide.
Cancer test - The New York Times writes about the GRAIL cancer detection study that the Knight Cancer Institute is part of, saying the tests screen for cancers that often go undetected, but they are expensive and some experts worry they could lead to unnecessary treatments without saving patients' lives. Tomasz Beer, M.D., says, "We're at a point now where the blood tests are in their early days. Some people in an informed manner can choose to be early adapters": Yahoo News, Advisory Board.
Pathfinder study – KGW News, KOIN TV, and the Portland Business Journal report on the progress of the Pathfinder study, led by Tom Beer, M.D.
Early cancer detection –- In a The New York Times profile on gene sequencing producer Illumina's purchase of Grail, a startup that developed a blood test for the early detection of dozens of kinds of cancer, Tom Beer, M.D., discusses the OHSU Knight Cancer Institute's leadership in a clinical research study in collaboration with Grail: "Where this field is going to shake out is hard to know. But this approach has a lot of underlying scientific promise."
Cancer patients -- A The New York Times article includes recommendations for patients with cancer from experts around the country, including Tom Beer, M.D.
Prostate cancer – In a video interview with UroToday, Tom Beer, M.D., is one of several expert panelists discussing the topics of depression, bone health, and exercise in patients with prostate cancer.
Cancer early detection – A Men's Health article describes an OHSU patient's experience with the Pathfinder study, aimed to detect many forms of cancer with a blood draw. The patient was diagnosed with both early-stage leukemia and a slow-growing prostate cancer. Study leader Tom Beer, M.D., said: "Early detection is a major challenge in cancer today. Nearly seven out of ten cancer deaths are due to cancers for which there is no early detection recommended at all. We're flying blind."
Prostate cancer therapy – Tom Beer, M.D., discusses OHSU's role studying a new FDA-approved therapy for patients with a form of prostate cancer. He says: "This is a significant new treatment for patients with prostate cancer who previously had few options. FDA approval of this therapy could be a lifeline for many patients, and I am proud that OHSU helped bring this treatment to patients who desperately need it": OHSU News.
Cancer therapy -- Tomasz M. Beer, M.D., discusses the benefits and side effects of available treatments for advanced prostate cancer: Patient Power.
Prostate cancer -- In a Cancer Therapy Advisor story on outcomes for prostate cancer patients with persistent PSA levels after salvage radical prostatectomy, Tom Beer, M.D., says: "I think the study points to the importance of careful selection of patients most likely to benefit from salvage prostatectomy. The procedure is best offered to patients who have a high probability of success."
Prostate cancer – In a video interview with UroToday, Tom Beer, M.D., is one of several expert panelists discussing the topics of depression, bone health, and exercise in patients with prostate cancer.
Targeted Oncology: Future Directions for the Treatment of mCRPC, October 19, 2021
Uro Today Video Lecture from ASCO 2021: Updated Interim Efficacy and Safety Results from a Phase I/IIa Trial HPN424 in Metastatic Castration-Resistant Prostate Cancer (mCRPC), June 16, 2021
Video Commentary - Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Non-metastatic CRPC, Journal of Clinical Pathways, February 23, 2021
2020
Pathfinder 1 study announcement: Investigational blood test could detect many types of cancer with one blood draw. Local coverage that published online included KATU-TV, KOIN-TV, KPTV story that was picked up by affiliates across the country, Portland Business Journal, KEX radio, San Francisco Business Times, FierceBiotech.
Cancer care during the pandemic – In a Renal & Urology News story on the impact of COVID-19 on prostate cancer care, Tom Beer, M.D., says: “Medical treatment for advanced cancer was universally treated as essential. We did not delay any hormonal therapy or chemotherapy or immunotherapy. And we did not delay participation and treatment in clinical trials. We were able to continue most of our clinical research."
Prostate cancer – In a Cancer Therapy Advisor article on cost-effective treatment options for patients with prostate cancer, Tom Beer, M.D., says “It’s quite reassuring that the quality-of-life years achieved and the total costs of care are quite similar across the choices.”
In a Portland Business Tribune article on how businesses were affected in 2020, Tom Beer, M.D., says “We've all had to adjust as we navigate the changing COVID-19 landscape, and the team at the Knight Cancer Institute was able to continue to offer cutting-edge clinical trial and treatment options for our patients who need it most."
Updates from ASCO Virtual 2020
Relugolix
Androgen Receptor Degraders
Patients Progressing on Androgen Receptor Inhibitors
Selecting treatment for nmCRPC
Androgen Receptor Inhibitors in nmCRPC
ASCO Poster Discussion Presentation: Putting Survival In Perspective - May 29, 2020
Video Commentary - Medicine Matters Oncology: Antiandrogens in nonmetastatic CRPC - May 31, 2020
Updates from the GU Symposium 2020
Atezolizumab and cabozantinib in mCRPC
Is PFS2 a legitimate endpoint?
TITAN study of apalutamide
OHSU News: Investigational blood test could detect many types of cancer with one blood draw - February 28, 2020
Portland Business Journal: OHSU chosen as site for early cancer detection study - February 18, 2020
KATU: OHSU looking for participants in cancer study - February 19, 2020
KPTV: Doctors at OHSU working on blood test for early cancer detection- February 19, 2020
KEX: OHSU Studying Cancer Blood Test- February 19, 2020
Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders - October 2, 2019
Editor Comments on OBR Daily I regularly comment on developments in prostate cancer
What Do Today’s Valuations Mean for Investors? Blog post on the White Coat Investor - April 10, 2019
Plenary Session Podcast Personal Finance for Physicians
Updates from the GU 2019
Plenary Session Podcast I am interviewed by Dr. Vinay Prasad on philanthropy and cancer research. Interview segment starts at the 12th minute
OHSU Opens New Cancer Center - Jefferson Public Radio Interview - November 7, 2018
Story Introduction
Audio Stream
The Link Between Apalutamide and QOL in Non-Metastatic CRPC - Cancer Network October 9, 2018
On importance of cancer research KPTV - September 8, 2018
Advances in Imaging, Therapies Bode Well for nmCRPC Management - Renal and Urology News, August 31, 2018
Prostate cancer screening: Middle ground may be reachable with latest recommendations—The Scribe. Ju
Updates from the ASCO 2018 Annual Meeting
OHSU Opens New Cancer Center - Jefferson Public Radio Interview - November 7, 2018
Story Introduction
Audio Stream
The Link Between Apalutamide and QOL in Non-Metastatic CRPC - Cancer Network October 9, 2018
On importance of cancer research KPTV - September 8, 2018
Advances in Imaging, Therapies Bode Well for nmCRPC Management - Renal and Urology News, August 31, 2018
Prostate cancer screening: Middle ground may be reachable with latest recommendations—The Scribe. Ju
Updates from the ASCO 2018 Annual Meeting
Immunotherapy in CRPC
PROSPER and SPARTAN studies
Multimodality treatment
Central themes at ASCO 2018
Under- and over-diagnosis
Buehler...? Buehler...? Buehler?—Oregon Business Magazine. February 28, 2018.
The $1B question: Can OHSU Really Cure Cancer?OPB. October 11, 2017.
Can a Building Help Cure Cancer?—OPB. October 11, 2017.
Did he really just tweet that? Dr. Vinay Prasad takes on Big Pharma, Big Medicine, and his own colleagues — with glee—STAT. September 15, 2017.
Should oncologists recommend hormone therapy plus abiraterone for patients with nonmetastatic prostate cancer?—HemOnc Today. September 10, 2017.
Dr. Vinay Prasad, OHSU's iconoclastic oncologist, calls out shoddy medicine—The Oregonian. September 7, 2017.
A taxpayer gamble on medical tourism: Louisiana subsidizes proton therapy to boost its economy—STAT. June 2, 2017.
The $1B question: Can OHSU Really Cure Cancer?OPB. October 11, 2017.
Can a Building Help Cure Cancer?—OPB. October 11, 2017.
Did he really just tweet that? Dr. Vinay Prasad takes on Big Pharma, Big Medicine, and his own colleagues — with glee—STAT. September 15, 2017.
Should oncologists recommend hormone therapy plus abiraterone for patients with nonmetastatic prostate cancer?—HemOnc Today. September 10, 2017.
Dr. Vinay Prasad, OHSU's iconoclastic oncologist, calls out shoddy medicine—The Oregonian. September 7, 2017.
A taxpayer gamble on medical tourism: Louisiana subsidizes proton therapy to boost its economy—STAT. June 2, 2017.